Bristol-Myers Squibb stock has rebounded strongly in 2024, driven by key drug approvals and positive financial performance, with shares rising from ~$40 to ~$60. The approval of Opdivo Qvantig, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback